Ono Pharmaceutical (OTCMKTS:OPHLF) Issues Quarterly Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) announced its quarterly earnings results on Monday. The company reported $0.21 earnings per share for the quarter, Zacks reports. Ono Pharmaceutical had a return on equity of 11.85% and a net margin of 19.64%.

Ono Pharmaceutical Stock Performance

Ono Pharmaceutical stock opened at $9.22 on Tuesday. The stock has a market cap of $4.33 billion, a P/E ratio of 6.88 and a beta of 0.59. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.80 and a current ratio of 3.22. Ono Pharmaceutical has a fifty-two week low of $9.22 and a fifty-two week high of $16.82. The firm’s fifty day moving average price is $10.38 and its 200-day moving average price is $12.49.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.